Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop treatments for fibro-inflammatory diseases.
Read the full article on the original site.
Read Full Article